Reference Product Sample Abuses: Indian Firms Flag Concerns With FTC
Executive Summary
Indian generic firms appear to be weighing in on controversy around brand name company tactics in the US to block access to reference products for bioequivalence testing – but generic firms may ultimately need legislation to resolve their concerns.
You may also be interested in...
Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting
Commissioner Gottlieb outlines several steps agency is taking – including potentially dropping requirement for shared REMS – to create more competitive generic marketplace.
FTC Backs Mylan’s REMS Antitrust Lawsuit Against Celgene
FTC files second amicus brief saying use of risk management programs to impede generic competition could violate antitrust laws; commission launched an investigation of Celgene four years ago.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.